FI118155B - Menetelmä hengityshäiriöiden hoitoon hyödyllisen terapeuttisesti vaikuttavan 4-hydrokdi-alfa1-[[[6-(4-fenyylibutoksi)heksyyli]-amino]metyyli]-1,3-bentseenidimetanolin 1-hydroksi-2-naftaleenikarboksylaatti(hydroksinaftoaatti)suolan valmistamiseksi - Google Patents

Menetelmä hengityshäiriöiden hoitoon hyödyllisen terapeuttisesti vaikuttavan 4-hydrokdi-alfa1-[[[6-(4-fenyylibutoksi)heksyyli]-amino]metyyli]-1,3-bentseenidimetanolin 1-hydroksi-2-naftaleenikarboksylaatti(hydroksinaftoaatti)suolan valmistamiseksi Download PDF

Info

Publication number
FI118155B
FI118155B FI932422A FI932422A FI118155B FI 118155 B FI118155 B FI 118155B FI 932422 A FI932422 A FI 932422A FI 932422 A FI932422 A FI 932422A FI 118155 B FI118155 B FI 118155B
Authority
FI
Finland
Prior art keywords
organic
hot
hydroxy
salt
hydroxynaphthoate
Prior art date
Application number
FI932422A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI932422A0 (fi
FI932422L (fi
Inventor
Steven Frederick Beach
David William Stuart Latham
Tony Gordon Roberts
Colin Brian Sidgwick
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of FI932422A0 publication Critical patent/FI932422A0/fi
Publication of FI932422L publication Critical patent/FI932422L/fi
Application granted granted Critical
Publication of FI118155B publication Critical patent/FI118155B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C07C217/10—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
FI932422A 1990-11-29 1993-05-27 Menetelmä hengityshäiriöiden hoitoon hyödyllisen terapeuttisesti vaikuttavan 4-hydrokdi-alfa1-[[[6-(4-fenyylibutoksi)heksyyli]-amino]metyyli]-1,3-bentseenidimetanolin 1-hydroksi-2-naftaleenikarboksylaatti(hydroksinaftoaatti)suolan valmistamiseksi FI118155B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB909026005A GB9026005D0 (en) 1990-11-29 1990-11-29 Drug material suitable for micronisation
GB9026005 1990-11-29
GB9102108 1991-11-28
PCT/GB1991/002108 WO1992009557A1 (en) 1990-11-29 1991-11-28 Benzenedimethanol suitable for micronisation

Publications (3)

Publication Number Publication Date
FI932422A0 FI932422A0 (fi) 1993-05-27
FI932422L FI932422L (fi) 1993-05-27
FI118155B true FI118155B (fi) 2007-07-31

Family

ID=10686212

Family Applications (2)

Application Number Title Priority Date Filing Date
FI932422A FI118155B (fi) 1990-11-29 1993-05-27 Menetelmä hengityshäiriöiden hoitoon hyödyllisen terapeuttisesti vaikuttavan 4-hydrokdi-alfa1-[[[6-(4-fenyylibutoksi)heksyyli]-amino]metyyli]-1,3-bentseenidimetanolin 1-hydroksi-2-naftaleenikarboksylaatti(hydroksinaftoaatti)suolan valmistamiseksi
FI982081A FI118203B (fi) 1990-11-29 1998-09-28 Menetelmä valmistaa farmaseuttinen 4-hydroksi-a1-[[[6-(4-fenyylibutoksi)-heksyyli]amino]metyyli]-1,3-bentseenidimetanolin 1-hydroksi-2-naftaleenikarboksylaatti-(hydroksinaftoaatti)suolaa sisältävä annosmuoto

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI982081A FI118203B (fi) 1990-11-29 1998-09-28 Menetelmä valmistaa farmaseuttinen 4-hydroksi-a1-[[[6-(4-fenyylibutoksi)-heksyyli]amino]metyyli]-1,3-bentseenidimetanolin 1-hydroksi-2-naftaleenikarboksylaatti-(hydroksinaftoaatti)suolaa sisältävä annosmuoto

Country Status (27)

Country Link
US (1) US5380922A (cs)
EP (2) EP0639176B1 (cs)
JP (1) JP3375626B2 (cs)
KR (1) KR100192196B1 (cs)
AT (1) ATE144244T1 (cs)
AU (1) AU644505B2 (cs)
BG (1) BG61340B1 (cs)
CA (1) CA2099586C (cs)
CY (1) CY2009A (cs)
CZ (1) CZ282996B6 (cs)
DE (1) DE69122780T2 (cs)
DK (1) DK0639176T3 (cs)
ES (1) ES2093812T3 (cs)
FI (2) FI118155B (cs)
GB (1) GB9026005D0 (cs)
GR (1) GR3022088T3 (cs)
HK (1) HK78997A (cs)
HU (1) HU218205B (cs)
IE (1) IE914146A1 (cs)
OA (2) OA09861A (cs)
PL (2) PL169722B1 (cs)
RU (2) RU2197475C2 (cs)
SG (1) SG49741A1 (cs)
SK (1) SK281095B6 (cs)
TW (1) TW309425B (cs)
WO (1) WO1992009557A1 (cs)
ZA (1) ZA919401B (cs)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9026005D0 (en) * 1990-11-29 1991-01-16 Glaxo Group Ltd Drug material suitable for micronisation
WO1993016031A1 (en) * 1992-02-11 1993-08-19 Glaxo Group Limited Benzenedimethanol derivative suitable for micronisation
US6254882B1 (en) 1997-09-16 2001-07-03 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol
JP2002541183A (ja) 1999-04-14 2002-12-03 グラクソ グループ リミテッド 医薬用エアゾール製剤
WO2002026239A1 (en) 2000-09-26 2002-04-04 Temple University Of The Commonwealth System Of Higher Education Analgesic and glucosamine compositions
EP2127641A1 (en) 2008-05-26 2009-12-02 Inke, S.A. Micronisable form of salmeterol xinafoate
KR101100614B1 (ko) 2010-09-20 2011-12-29 한국수력원자력 주식회사 농축폐액 건조물의 펠렛화 장치 및 방법과 이를 이용한 유리조성개발 방법
WO2016142582A1 (en) 2015-03-11 2016-09-15 Fermion Oy Process for the preparation of crystalline salmeterol and its xinafoate salt

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
GB9026005D0 (en) * 1990-11-29 1991-01-16 Glaxo Group Ltd Drug material suitable for micronisation

Also Published As

Publication number Publication date
BG61340B1 (en) 1997-06-30
FI932422A0 (fi) 1993-05-27
KR100192196B1 (en) 1999-06-15
FI982081A0 (fi) 1998-09-28
CY2009A (en) 1998-02-20
US5380922A (en) 1995-01-10
EP0639176B1 (en) 1996-10-16
DK0639176T3 (da) 1996-12-23
TW309425B (cs) 1997-07-01
CZ101993A3 (en) 1994-01-19
CA2099586C (en) 2002-06-25
CZ282996B6 (cs) 1997-12-17
ZA919401B (en) 1992-07-29
OA10024A (en) 1996-10-14
SK54593A3 (en) 1993-10-06
DE69122780D1 (de) 1996-11-21
CA2099586A1 (en) 1992-05-30
OA09861A (en) 1994-08-15
EP0571669B1 (en) 1996-03-06
BG97767A (bg) 1994-12-02
EP0571669A1 (en) 1993-12-01
HUT64219A (en) 1993-12-28
PL169722B1 (pl) 1996-08-30
GR3022088T3 (en) 1997-03-31
ES2093812T3 (es) 1997-01-01
EP0639176A1 (en) 1995-02-22
JPH06503082A (ja) 1994-04-07
SG49741A1 (en) 1998-06-15
GB9026005D0 (en) 1991-01-16
PL167976B1 (pl) 1995-12-30
FI118203B (fi) 2007-08-31
RU2197475C2 (ru) 2003-01-27
HK78997A (en) 1997-06-20
AU644505B2 (en) 1993-12-09
AU9040291A (en) 1992-06-25
HU9301568D0 (en) 1993-09-28
RU2116293C1 (ru) 1998-07-27
JP3375626B2 (ja) 2003-02-10
FI982081L (fi) 1998-09-28
DE69122780T2 (de) 1997-02-20
ATE144244T1 (de) 1996-11-15
HU218205B (hu) 2000-06-28
IE914146A1 (en) 1992-06-03
FI932422L (fi) 1993-05-27
SK281095B6 (sk) 2000-11-07
WO1992009557A1 (en) 1992-06-11

Similar Documents

Publication Publication Date Title
JP2650807B2 (ja) 複素環式化合物
JPH11503448A (ja) 吸引可能粒子の製造法
US9351957B2 (en) Amorphous form of apremilast
FI118155B (fi) Menetelmä hengityshäiriöiden hoitoon hyödyllisen terapeuttisesti vaikuttavan 4-hydrokdi-alfa1-[[[6-(4-fenyylibutoksi)heksyyli]-amino]metyyli]-1,3-bentseenidimetanolin 1-hydroksi-2-naftaleenikarboksylaatti(hydroksinaftoaatti)suolan valmistamiseksi
JP2009515830A (ja) 微粉化アゾジカルボンアミド、その調製及びその使用
WO2003090693A2 (en) Pharmaceutical composition containing lamotrigine particles of defined morphology
AP323A (en) Drug material suitable for micronisation.
EP2303232B1 (en) Micronisable form of salmeterol xinafoate
WO1993016031A1 (en) Benzenedimethanol derivative suitable for micronisation
IL101798A (en) 1-hydroxy-2-naphthalene carboxylate (hydroxynaphthoate) salt of 4-hydroxy- alpha1-[[[6-4-phenylbutoxy) hexyl] amino] methyl]-1,3-benzenedimethanol suitable for micronisation
EP4164595B1 (en) Anatabine powder compositions
CN114469979B (zh) 一种核糖核苷类似物的药物组合物、吸入剂及其应用
RU2844716C1 (ru) Анатабиновые композиции в виде порошка
SI9200252A (sl) Zdravilni material, primeren za mikronizacijo
JP2019521974A (ja) ラクトースと臭化グリコピロニウムの結晶性医薬品共結晶
WO2025032259A1 (en) Crystalline compositions
CN1056974C (zh) 适宜于微粒化的药物材料的制备方法
NZ240788A (en) 1-hydroxy-2-naphthalene carboxylate salt of 4-hydroxy- alpha 1

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 118155

Country of ref document: FI

MA Patent expired